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Considerable structural  similarities  are  present  in a 
region of approximately 270 amino acids in most 
known cyclic nucleotide  phosphodiesterase  (PDE) se- 
quences, opening the possibility that  this  region  en- 
codes the  catalytic domain of the enzyme. To  test  this 
hypothesis, the  structure of a  high affinity cAMP PDE 
(CAMP-PDE) was  analyzed by deletion  mutations  and 
site-directed  mutagenesis.  A ratPDE3 cDNA was mu- 
tated using  a strategy based  on fragment  amplification 
by polymerase  chain  reaction. The  effect of the  intro- 
duced  mutations  was  determined  by  expressing  wild 
type  and  mutated  proteins  in  prokaryotic  and  eukary- 
otic cells. The level of expression of the PDE  protein 
was monitored by immunoblot analysis  using  two  spe- 
cific CAMP-PDE polyclonal antibodies  and  by meas- 
uring  the PDE  activity.  After  removal of a 99-amino 
acid  region at  the carboxyl  terminus  flanking  the con- 
served domain, the  protein  retains  its  catalytic  activity 
even though its K,,, and velocity were changed. Internal 
deletions at  the  amino  terminus of this  PDE showed 
that  the enzyme activity was increased when a 97- 
amino acid fragment (from Tyr4’ to Lys14‘) was re- 
moved. Further deletions within  the  amino  terminus 
produced inactive proteins. Within the domain that 
appears  essential  for  catalysis, 1 threonine  and 2 serine 
residues are conserved in all PDEs. Substitutions of 
the invariant threonine (Thr349) present in the most 
conserved  region  with  alanine,  proline, or serine 
yielded proteins of the correct size and a level of 
expression  comparable  to  the  wild  type PDE. However, 
in both  expression  systems  used,  proteins  were com- 
pletely devoid of the  ability  to  hydrolyze cyclic nucle- 
otides,  except  when  the  threonine  was  substituted  with 
a serine.  Conversely,  mutations of 2 other conserved 
serine  residues (Ser3’‘ and SerSs8) present  in  the  cata- 
lytic domain either  had no effect or produced  changes 
only in K ,  and V,,,,,, but did not abolish catalytic 
activity.  In  addition,  2  histidine  residues (His278 and 
His311) present  in  proximity  to  Thr349  appeared  to  be 
essential  for  the  structure of the  catalytic domain,  since 
any substitution  performed  in  these  residues yielded 
an  inactive enzyme. Mutations of a serine residue 
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(Ser296)  in  the  region homologous to  the cAMP binding 
site of the  regulatory  subunit of the CAMP-dependent 
protein  kinase  demonstrated  that  this  region  does not 
have  the  same function  in the  two proteins.  These data 
provide  direct  evidence  that  a  37-kDa  domain,  which 
in part corresponds  to  the region of conservation  in  all 
PDEs,  contains  the  catalytic domain, and  that  threo- 
nine  and  histidine  residues are probably  involved  in 
catalysis  and/or are essential  for  the  conformation of 
an  active enzyme. 
Intracellular  inactivation of the second  messengers cAMP 
and  cGMP  is  dependent  on cleavage of the  phosphodiester 
bond of the cyclic phosphate  ring by specific cyclic nucleotide 
phosphodiesterases  (PDEs).’  These enzymes constitute a 
complex family of forms that can be distinguished on the 
basis of their  catalytic  properties  and regulation (1, 2). The 
recent  acquisition of the  primary sequences of a number of 
PDEs  has provided new insight  into  the  structure of these 
enzymes. Knowledge of the structure of the catalytic and 
allosteric sites is needed especially in view of the  fact  that 
these enzymes are  targets for a  large number of drugs. More- 
over, pharmacological modulation of the PDE activity is a 
primary  tool for manipulating  intracellular cyclic nucleotide 
levels. 
With  the exception of the Dyctiostelium discoideum PDE 
(3) and the Saccharomyces cereuisiae PDEl  (4), all other 
PDEs possess  a region of approximately 270 amino acids  in 
which homology is  present. Sequence alignment of this  con- 
served region of these  proteins reveals that 45 residues (61 if 
the  yeast low K ,  PDE (5) is  not considered  due to  its  smaller 
conserved  region) are  identical or chemically  conserved among 
15 different sequences  available  (6,  7). This  observation sug- 
gests that  the 270-residue region of the enzyme has a  common 
function, possibly that of catalysis. Controlled proteolysis 
studies on the calmodulin-dependent PDE (CaM-PDE’) (8, 
9) and  the  cGMP-stimulated  PDE  (cGS-PDE’) (10-12) have 
revealed that  the  functional  domain of these  proteins  can be 
separated from regulatory domains. In both cases limited 
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proteolysis  produces 30-40-kDa fragments  that  are  catalyti- 
cally active and  are  no longer activated by calmodulin and 
cGMP, respectively. Furthermore,  these  fragments  are known 
to include the conserved region of PDEs. The presence of 
separate regulatory and  catalytic  domains, however, has  not 
been explored for the CAMP-specific PDE (CAMP-PDE’), 
even  though  this group of PDEs  has been  shown to be regu- 
lated by hormones and neurotransmitters (see Ref. 13 for 
review). 
Within  the conserved region, the low K,,,, CAMP-specific 
PDEs including the Drosophila melanogaster dunce  PDE  (14) 
and  the four rat  CAMP-PDEs (15) contain a short sequence 
(ELALMYN) also present  in  the RII,  regulatory subunit of 
CAMP-dependent protein kinase. I t  is intriguing that this 
sequence in the RII, subunit is thought to be involved in 
cAMP binding by forming a hydrogen bond between the 
conserved glutamate residue (E)  and  the 2”hydroxyl  group of 
the ribose ring of  CAMP (16). Cyclic AMP  binding is abolished 
when  the enzyme conformation  is  changed following the  sub- 
stitution of the conserved glycine, the residue adjacent  to  the 
glutamate, with glutamic or aspartic acid residue (17-19). 
Whether  this homology in  the sequence of the  CAMP-PDEs 
has a similar role is  not known. Here we report  experiments 
examining possible implications of this  7-amino acid  sequence 
homology in  CAMP-PDEs. 
Sequence analyses also have shown that out of the 45 
conserved residues 5 positions  are occupied by histidine (6, 
7), suggesting the  importance of these residues in  the enzyme 
function. Epstein et al. (20) have investigated the kinetic 
properties of a CAMP-PDE from dog kidney and reported 
data  consistent with the presence of a histidine  and a sulfhy- 
dryl group in  the active site of the enzyme. Studies  on  sub- 
strate specificity of the beef heart  CAMP-PDE have  led to  the 
conclusion that hydrolysis of cAMP probably takes place by 
two nucleophilic substitution  reactions  initiated by  a  nucleo- 
philic  group of the enzyme  (21). This  mechanism recently has 
been agreed upon by Van Lookeren Campagne et al. (22) who 
studied the yeast low K,,, CAMP-PDE. Thus, amino acid 
residues that are conserved in all known PDEs and also 
possess a nucleophilic group such as serine, threonine, and 
histidine are thought to be directly involved in catalysis. 
Furthermore,  studies  on  the bovine intestinal 5’-nucleotide 
phosphodiesterase  have shown that a threonine residue is  the 
active site of the enzyme. This residue forms a covalent 
phosphothreonine intermediate in the catalytic mechanism 
(23). 
The purpose of this study was to  test  the following hy- 
potheses: 1) to  determine if the conserved domain  corresponds 
to  the catalytic  domain of the  CAMP-PDE; 2) to  test if the 
region of homology with  the RII, regulatory subunit behaves 
as in the CAMP-dependent protein kinase; 3) to examine 
which  residue@) among  the conserved threonine,  serine,  and 
histidine are important for the enzyme activity. For this 
purpose deletion and site-directed mutations of a low K, 
CAMP-specific PDE,  ratPDE3 (24), were performed  using  the 
polymerase chain  reaction  technique.  The  rationale for choos- 
ing  ratPDE3  protein for this  study  is  that  the  corresponding 
cDNA  contains  the  entire  open  reading  frame which  encodes 
a CAMP-PDE of 584 amino acids  (24). This  protein  has been 
successfully expressed in prokaryotic and eukaryotic cells, 
and  this is the  form  that we have  characterized extensively 
and found to be indistinguishable from  the  CAMP-PDE  en- 
dogenous in  the  Sertoli cell (24, 25). 
EXPERIMENTAL  PROCEDURES 
Materials-Reagents were purchased from the following compa- 
nies: Taq DNA polymerase, Perkin-Elmer/Cetus, Nonvalk,  CT; 
dNTP  and  the large fragment of Escherichia coli polymerase I, Be- 
thesda Research  Laboratories (BRL); T4 DNA ligase, New England 
Biolabs; Crotalus atrox snake venom, lysozyme, and  CAMP, Sigma; 
RO 20-1724 (4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone), 
Hoffmann-LaRoche;  rolipram (4-[3-(cyclopentyloxy)-4-methoxy- 
phenyl]-2-pyrrolidone), Berlex, NJ; [2,8-3H]cAMP (20-50 Ci/mmol), 
‘*‘I-protein A (2-10 gCi/gg), and [35S]dATP (1000 Ci/mmol), Du 
Pont-New England Nuclear; Immobilon, Millipore; pZ523 column, 
5prime-3prime Inc.; Pansorbin cells, Calbiochem Corp.; AG 1-X8 
resin,  Bio-Rad.  Restriction enzymes were from either Bethesda  Re- 
search Laboratories or United States Biochemical Corp. Milrinone 
(1,6-dihydro-2-methyl-6-oxo-(3,4’-bipyridine)-5-carbonitrile) was 
provided by Glaxo Inc., Research  Triangle Park, NC. 
PCR Primers-For the  sake of simplicity, the oligonucleotides used 
for PCR amplification are identified by letters  as listed below. The 
positions of the oligonucleotides used for deletion mutation  are re- 
ported in Fig. 1 together  with the complete nucleotide and deduced 
amino acid sequences of ratPDE3. 
A = 5‘GACGGAATTCAATATGACTCTAGAAGACCATTA3’; 
where the EcoRI site, the translation initiation sequence, and the 
XbaI site are underlined in order. The 21 nucleotides at  the 3’ end 
including the ATG codon and  the XbaI site correspond to  the  rat- 
PDE3-specific sequence from nucleotide 822 to nucleotide 842 (see 
Fig. 1). The EcoRI site was added to correspond to  the EcoRI site 
present in the expression vector, and to allow the creation of the 
deletion from the 5’ end  to base 822 of ratPDE3 cDNA (see Fig. 2). 
The native ATG codon preceding the XbaI site was used to  initiate 
the  translation of the  amino-terminal  truncated  proteins  thus gen- 
erated. For the purpose of prokaryotic  expression, the sequence AAT 
located between the EcoRI site and the ATG codon was added to 
correspond to  the sequence in  the wild type construct (detailed below). 
B = 5’ AGGCAAGCTTACTGGTACCACTCACGATTGT 3’ ; 
where the  HindIII  site  and  the KpnI site  are underlined in order. The 
20 nucleotides at  the 3’ end including the KpnI site correspond to 
the antisense sequence of the ratPDE3 from nucleotide 1605 to 
nucleotide 1586 (see Fig. 1). The  HindIII  site was added to correspond 
to  the  HindIII  site  in  the expr ssion vector and  to allow the generation 
of the deletion from the 3’ end  to  the KpnI site of ratPDE3 cDNA 
(see Fig. 2). For these carboxyl-terminal truncated proteins, the 
introduced stop codon (TAA), which overlaps the  HindIII  site, was 
used to  terminate  the  translation. 
C = 5’ ACGAGGCCTTGATGCACAGCTCCAGC 3’; where the 
StuI site is underlined and is followed  by the ratPDE3-specific 
sequence from nucleotide 587 to 603. 
D = 5’ CCAGCAGATTCATGTGC 3’, which corresponds to  the 
antisense sequence of the  ratPDE3 cDNA from nucleotide 1225 to 
1209. 
E = 5’ ACGAGGCCTGGGGCCTCCACGTTTTCC 3’; where the 
StuI site is underlined and is followed  by the ratPDE3-specific 
sequence from nucleotide 689 to 706. 
F = 5’ ACGAGGCCTTTAAAATCCCAGTGGACAC 3’; where the 
StuI site is underlined and is followed by the ratPDE3-specific 
sequence from nucleotide 788 to 806. 
Oligonucleotides A  through  F were used to  create deletion muta- 
tions of the  ratPDE3 cDNA using PCR technique. PCR fragments of 
807, 648, 546, and 838 bp were amplified by using  paired  primers, A 
and B, C and D, E and  D,  and F and  B, respectively, in which primers 
C, E,  and F were designed to  contain a StuI site at  their 5’ ends in 
order to generate internal deletions  (see Figs. 2 and  3). 
The following primers were synthesized to produce site-directed 
mutations of the  ratPDE3. 
G = 5’ GAGAATCAT(A/G/T)ATTTGGCTGT 3’; where the  sin- 
gle mutated base  is underlined. These  three mixed oligonucleotides 
correspond to  the  ratPDE3 cDNA from nucleotide 1072 to 1091. 
H = 5’ ACAGCCAAAT(A/C/T)ATGATTCTC 3’; where the mu- 
tated base  is underlined. These oligomers correspond to  the antisense 
sequences of oligomers G. 
Oligomers A, B, G, and H were used as primers in PCRs in order 
to  obtain  mutations of His3” to Asn, Asp, and  Tyr (His3”/Asn, His311/ 
Asp, and  His3”/Tyr). 
I = 5’ GTACTAGCG(T/G/C)CAGACATGTC 3’; where the mu- 
tated base is underlined. These oligomers correspond to  the  ratPDE3 
cDNA sequence from base 1186 to 1205. 
J = 5’ GACATGTCTG(G/C/&)CGCTAGTAC 3’; where the mu- 
tated base is underlined. These oligomers correspond to  the  antisense 
sequences of oligomers I. 
The use of oligomers A, B, I, and J in PCRs was able to generate 
-~
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CCGCCGlCCCCClGCCMA~llGGCCllGCAGCAClllGCGCCCClCCClGGAGGClGACCCGCMCGlCAAGClGGAGCAlClCGGCCAGCCl~GCCCGGCCCCACl~lCCMCClC 
60 . 120 
A~tCCCCCGCGC~CtGCC~~GClClGCAAlAl~GGAGCAGCCClCAlGlGCGGGCACCGGGCAlCCGAGCAlGGCGGGGlACGGCAG~lGGCCCCClllGMClCGClGGlGGlCCG 
. 180 . 240 
region missing in reIPDE3.2 EcoRI 
UElLysClutlnProserCysllsGlylhrGlyHisPrnSerMetAlaGlyly~GlyA~gU~tAlaProPheGluLeuAl~Gl~lyPro 30 
FIG. 1. Nucleotide and deduced 
amino acid sequences of ratPDE3 
cDNA. Nucleotide numbers  are  re- 
ported above the sequence. Deduced 
amino acid  residue numbers  are reported 
to  the right of the  amino acid  sequence. 
Nucleotides underlined in  the sequence 
correspond to restriction sites used for 
the various constructs  detailed  under 
“Experimental Procedures.” The name 
of the corresponding restriction enzyme 
is  reported below the sequence. The  se- 
quences of the oligonucleotides used to 
construct  deleted  proteins (see “Experi- 
mental Procedures” for details) are re- 
ported above the cDNA sequence. Re- 
striction  sites  present  in  the oligonucle- 
otides  are underlined. The  arrow  next  to 
the StuI restriction  site  marks  the b gin- 
ning of the  internal deletion. Amino acid 
residues underlined are  targets for site- 
directed mutagenesis. Small  arrows  mark 
sequence missing in  the  ratPDE3.2 
cDNA. A  nucleotide  sequence corre- 
sponding  to  an EcoRI restriction  site  is 
reported above the cDNA  between bases 
142 and 147. This sequence was intro- 
duced in the  native  ratPDE3 cDNA by 
PCR mutagenesis.  Digestion of the  mu- 
tated cDNA with EcoRI causes the re- 
moval of 147 bases of the 5’ untranslated 
sequence. 
GCCAlTlll~CtAGlGCAAlACAlGAlGlGGAlCAlCClGGlGlGlCAAAlCAAlllClGAlCAAlACAAAClCGGAACllGCCllGAltlACAAC~ClCClCCGlCllAGA~lCAl 
. 1020 . 1080 
AlallePheAlaSerAlalle~~spValArpHirProClyValserAsnClnPheLeulleAmlhrAsn~GluLeuAlsLeLHeflyrAsnAspSer~ValL~~GlUPIsnHis 310 
CAlllG~Cl~lGGCClTTAAGllGClCCAGGAAGAAAAClGlGACAllllCCAGAAlClGACCMAAAGCAAAGACAAlClllAAG~AAAlGGCCAllGACAllGlAClAGCGACAMC 
. 1140 . 1200 
- HisLeuAlaValClyPheLysLeuLeuGlnGluGluAsnCysAspllePheCl~snLeulhrLysLy~Gl~rgGlnSerLeUPI~gLy~M~tAlalleAsplleValLeuAla~Asp 350 
oligo D CGTCTACTTACGACACC 
ATCTCAAACCACATCAATClGClGGClGAlClG~CAAlGGllGAAACGAAGMGGlMCMGClClGGCGlCClCClCCllGAlAAC~AllCl~CAGGAlCCAGGlCClCCAGMl 
. 1260 . 1320 
H e t S e r L y s H i S M e t A S n L e Y L e u A L a A s p L e u L y s l h r M e t V a l G l ~ l h ~ L y ~ L y ~ V ~ l l h ~ S e ~ S e ~ G l y V ~ l L ~ ~ L ~ u L e U P I s ~ s n l y ~ S e ~ A ~ ~ ~ g l ~ e G l n V a l L e u G l ~ s ~  390 
AlCClGCACTClGCAGACCl~GCAACCCCACMAGCCAClCCAGClClACCGCCAGlGGACGGACCGGAlAAlGGAGGAGllCllCCGlCAGGGGGACCGGGAGCGlGAGCGlGGlACG 
. 1380 . 1440 
~ e t V a l H i s C y S A I a A S p L e ~ ~ A ~ ~ P ~ ~ l h r L y s P r o L e u ~ l n L e u l y r A r g C l ~ l ~ p l h ~ A ~ ~ r g l l ~ e t G l u G l u P h e P h e A r g G l f f i l y A ~ ~ ~ g G l U P I r g G l u A ~ g G l ~ e t  430 
GAGAlAA~lCCCAlGlGlGACAA~CACAACGCClClGlGGAAMAlCACAGGlGGGCllCAlAGAClACAllGllCAlCCAClClGGGAGACAlGGGCAGACClCGlACAlCCCGACGCC 
. 1500 . 1560 
G l U l l e S ~ ~ P r O n e t C y s A s p L y s H i s A s n A l a S e r V a l G l u L y s S ~ ~ G l ~ V a l G l y P h ~ l l ~ A ~ p l y ~ l l e V a l H i ~ P ~ ~ L ~ ~ l ~ p G l u l h r l r ~ l ~ A ~ p L e u V a l H i s P ~ n A ~ ~ l ~  470 
o1;go 8 TGTTAGCACTCACCATGGTCRTTCGII\CtGP, 
C A G G A C A l l l l G G A C A C l l l C C A G C A C M l C G T G A G l ~ A G A G C A C A A l C C C C C A G A G C C C C l C C C C l G C A C C l M l G A C C A A G A G G A C G G C C G l C A G G M C A G A C l G A A A A A l l C  
. 1620 . 1680 
G l n A ~ p l l e L e ~ s p l h r L e u G l u A s ~ s ~ r g G l u l r p l y r G l n s ~ ~ l h ~ ~ l e P r o G l n S ~ ~ P ~ ~ s ~ ~ P ~ n A l a P ~ ~ A ~ ~ ~ p G l ~ G l u A s ~ l y A ~ g G l ~ G l y G l n l h r G l u L y ~ P h ~  510 
Kpnl 
CAGTTCGAACTAACCTTAGAGGMGAlGGCGAGl~GACAC~GMAAGGACAGlGGAAGlCMGlGGAGGAAGACAClAGClGCAGlGAClCTAAGAClClGlGCACCC~~ClCAGAC 
. 1740 . 1800 
GInPheGLuLeulhrLeu~luCLu(\spCLyGloSerAsplhrCLuLysAepSer~LySerClnValGluGluAspThrSerCysSerAspSerLysTh~LeucysTh~GlnA~pSerGlu 550 
TCCACTCAAAT~CCCCTTGACGAGCAG~TTGAAGAGGAGGCT~TAGCAGAAGAGGAAAGCCAGCCCCAAACTGGCGTCG~GACGATTGTTGTCCTGACACGTAACAGTGTMAGGCTGT 
S e ~ T h r G l ~ I l e P r o L e ~ s p G l u C l n V s l G L u t l u t l u A L a Y s l A l ~ G l ~ G l u G l u S ~ ~ G l ~ ~ ~ G l ~ l h ~ G l y V a l A l ~ A ~ ~ ~ ~ y s c y s P ~ ~ A ~ p l h ~  
. 1860 . 1920 
CACACCTTllClllllCTlllllllllllAAAGlAMMAAAA 
mutations of Thr:j4’ to  Ser, Ala, and  Pro (Thr”’/Ser, Thr349/Ala,  and 
Thr”’/Pro). 
K = 5’ CAACGACTCC(&)CCGTCTTAGAG 3’; where the  mu- 
tated base was underlined. These two oligomers correspond to the 
ratPDE3 cDNA  sequence from  base 1053 to 1074. 
L = 5’ CTCTAAGACGG(G/T)GGAGTCGTTG 3’; where the 
mutated base is underlined. These oligomers correspond  to  the  anti- 
sense sequences of oligomers K. 
Oligomers A, B, K, and L were employed in PCRs in order to 
produce  mutations of Ser305 to  Thr  and  Pro (Ser305/Thr and Ser3OS/ 
Pro). 
M = 5’ AATACAAACG(A/G)GGAACTTGC 3’; where the two 
mutated bases are underlined. These oligomers correspond to the 
ratPDE3 cDNA  sequence from  base 1024 to 1043. 
N = 5’ GCAAGTTCC(G/T)CGTTTGTATT 3‘; where the two 
mutated bases are underlined. These oligomers correspond to the 
antisense sequences of oligomers M. 
Oligomers A, B, M, and N were used to  obtain  mutations of SerZg5 
to  Gly and Glu  (Ser2”/Gly and  SerZg5/Glu). 
0 = 5’ CCACATCAaTATTGCACTG 3’; where the two mutated 
bases are underlined. This oligomer corresponds to the antisense 
sequence of the  ratPDE3 cDNA from  base 991 to 972. 
Using oligomers A and 0 in a PCR, a 183-bp  fragment was 
amplified, in which the HisJ7’ codon was mutated  to encode alanine 
(His”“/Ala).  This  PCR  fragment  (also called megaprimer (26))  and 
oligomer B were then employed as primers in the second round of 
PCR to produce  a fragment that contained  the base substitution. 
P = 5’ GCAGACCTGSCAACCCCAC 3‘;  where the two mutated 
bases are underlined. This oligomer corresponds to the ratPDE3 
cDNA  sequence from base  1333 to 1352. 
As oligomer 0, oligomer P also was designed to  generate a  mega- 
primer.  In  the presence of oligomers  B and  P, a PCR  fragment of 284 
bp was  amplified, in which the Ser”’ codon was substituted with an 
Ala codon (Ser”’/Ala). 
PCR Amplification and  Product Purification-PCR  was  performed 
using Taq polymerase and a DNA thermal cycler (Perkin-Elmer/ 
Cetus). Amplification was achieved using conditions provided by 
Perkin-Elmer/Cetus. Briefly, in a  final volume of  100 p l ,  the reaction 
mixture  contained 10 mM Tris-C1, pH  8.3,50 mM KC1, 1.5 mM MgC12, 
0.01% (w/v) gelatin, 200 p~ each of dNTP, 1 p~ of each  primer, 5- 
10  ng of template  (ratPDE3 cDNA for both deletion and  site-directed 
mutations),  and 2.5 units of Taq polymerase. Reactants were overlaid 
with 50 p1 of mineral oil and subjected to 10-15 cycles of denaturation 
(1 min, 94 “ C ) ,  annealing (2 min,  55  “C),  andextension  (3  min, 72 “C). 
The  PCR  products were electrophoresed on a 1% agarose gel (1.5% 
for the products shorter than 300 bp), followed by staining with 
ethidium bromide and visualizing with UV light. DNA bands of 
correct sizes were cut  out  and removed from  the gel by electroelution 
(unidirectional  electroelutor,  International Biotechnologies Inc., New 
Haven,  CT). 







Restriction  digestion 
Enzymes used 9 Kpnl Mhdll 
Xbal. Hindlll 
Econl. Kpnl ”7 E& xb.l 
B O P  
MU 
E M  xb.l 
EcoRI, Hindlll 
WI niml 
B O P  
E M 1  Xb.1 
B %hzmZ&&”lmii MU 
ECOR~ x td  
C 
np i l  nimlll u
MU Slap 
em mnseNed domain 
FIG. 2. Schematic representation of the strategy  used for 
generation of terminal  deletions of ra tPDE3.  A, structure of 
prokaryotic expression vector, pRC23, bearing the  ratPDE3 cDNA 
inserted at  the EcoRI site. The  ratPDE3 cDNA has been modified to 
shorten  its  5’-untranslated sequence as described under  “Experimen- 
tal Procedures.” E ,  to determine if the conserved, domain (hatched 
bar) corresponds to  the catalytic  domain of ratPDE3,  mutants with 
deletions of 5’ and/or 3’ domain were generated  using PCR technique. 
A  pair of oligonucleotide primers (oligoA and oligoB) were designed 
t o  produce a  PCR  fragment of 807 bp using the  ratPDE3 cDNA as 
template.  The complete sequences of  oligoA and oligoB are reported 
under “Experimental Procedures” and in Fig. 1. The  PCR product 
contains  the EcoRI site, translation initiation codon (ATG), and XbaI 
site  at  its 5’ end and  the  KpnI site, stop codon (TAA), and  HindIII 
site  at  the 3’ end. The  PCR fragment was digested with XbaI and 
HindIII enzymes (for construct A) or EcoRI and HindIII enzymes 
(for construct C), and then inserted into the expression vector, 
pRC23-ratPDE3, to replace the corresponding wild type fragment. 
To  prepare construct B, the  PCR fragment was digested with EcoRI 
and KpnI enzymes. A KpnI-Hind111 fragment  (approximately 390 bp) 
encoding the carboxyl terminus of the  protein was also excised from 
the wild type pRC23-ratPDE3  and was purified from an agarose gel. 
These two restriction  fragments were then ligated to  the vector that 
has been digested with EcoRI and  HindIII followed by dephosphoryl- 
ation. The assembly of this construct was verified by restriction 
mapping and DNA sequencing of the ligation sites. Plasmids thus 
constructed have deletions of ratPDE3 cDNA at  the 3‘  end (construct 
A, corresponding to carboxyl-terminal  99-amino  acid  deletion), at  the 
5’ end (construct B, corresponding  to  amino-terminal 224 amino acid 
deletion),  or at  both 5’ and 3‘ ends  (construct  C). 
To create  deletion mutations of the  ratPDE3 cDNA, paired  primers 
(oligomers A and B; C and D; E and D; and F and  B) were used in 
PCR (Figs. 1 and 3). For site-directed mutations, either three primers 
(megaprimer method, (26)) or four primers (overlap method, (27)) 
and two rounds of PCR were employed. Details of this PCR-based 
mutagenesis  strategy have been described elsewhere (26, 27). 
Prokaryotic Expression Vector and Mutation Constructs-To ex- 
press wild-type and mutated ratPDE3 in bacteria, the prokaryotic 
expression vector pRC23 (28) was used. The plasmid pRC23 contains 
a synthetic Shine-Dalgarno ribosomal binding sequence, which is 
located downstream from the tightly regulated phage PL promoter 
(Fig. 2 A ) .  The  SD sequence is immediately followed by the EcoRI 
site where the  ratPDE3 cDNA has been inserted (Fig. 2 A ) .  Since the 
distance between the ribosomal binding site  and  the AUG codon is 
critical  for transcription efficiency (29), the  ratPDE3 cDNA has been 
modified by removing the  untranslated sequence of 147 bases from 
the 5’ end of the cDNA using PCR technique  (detailed in Ref. 25). 
The resulting  1.8-kb ratPDE3 cDNA encoding the wild-type ratPDE3 
enzyme has its AUG codon only 3  bases (AAT, from base 148 to 150) 
3’ to the EcoRI site (see Fig. 1). This ratPDE3-bearing plasmid, 
designated pRC23-ratPDE3 (Fig. 2 A ) ,  was used in the present  study 
to create the  mutation  constructs. 
To prepare mutation constructs, PCR fragments were digested 
with appropriate restriction enzymes (as shown in Figs. 2 and 3), 
analyzed by agarose gel electrophoresis, and eluted from the gel. 
These purified fragments were inserted into pRC23-ratPDE3 that 
has been digested with the same restriction enzymes followed by 
dephosphorylation.  One  exception was the  construct B shown in Fig. 
2A where the restriction enzymes for the pRC23-ratPDE3 were 
different from those for the  PCR fragment (see Fig. 2A legend). 
Transformation and Recombinant PDE Expression-E. coli strain 
DH5a and its plasmid-bearing derivative DH5a(pRK248cIts) were 
used for transformation.  The hybrid plasmid pRK248cIts  is  compat- 
ible with the expression vectors derived from pBR322 (30). It  contains 
the  cIts gene encoding a  temperature-sensitive  repressor (cIts) which 
acts in trans on the phage PL promoter  present in the pRC23 expres- 
sion vector to prevent  expression from the promoter at  the nonper- 
missive temperature of 30 “C. DH5a(pRK248cIts) cells were trans- 
formed with the wild type (pRC23-ratPDE3)  and  mutant constructs 
using the procedure described by Maniatis et al. (31). Cells were 
grown at  30 “C  at which the  ratPDE3 enzyme was not expressed due 
to  the presence in the cell of the  cIts repressor that controls the PL 
promoter. Transformants were selected on  ampicillin-containing me- 
dium. 
Individual colonies (6 to 29) were picked from each transformation. 
Cells were grown at  30 “C  and  then stored  as frozen stocks at  -80 “C. 
Each bacterial clone was screened for PDE expression by PDE assay 
and by Western  blot  analysis.  Expression of ratPDE3 in bacteria was 
achieved by shifting  incubation temperature from 30 to 42 “C. After 
3  h at  42 “C,  the cells were pelleted and lysed in 1X  sample buffer for 
Western blot analysis  (detailed below). For PDE assay, the bacterial 
pellet was resuspended and lysed for 15 min in a buffer containing 20 
mM Tris-C1, pH 8.0, 1 mM EDTA, and 2.2 mg/ml lysozyme. The cell 
lysate was then adjusted to also contain 0.2 mM EGTA, 10 mM NaF, 
50 mM benzamidine, 0.5 pg/ml leupeptin, and 0.7 pg/ml pepstatin. 
Isolation of Plasmid and DNA Sequencing Analysis-Plasmid 
DNAs were isolated from mutant clones using the alkaline lysis 
method provided by the manufacturer (5prime-3prime, Inc.), and 
were mapped using  restriction enzyme analysis to confirm that  the 
correct DNA fragment  had been inserted.  For  site-directed  mutation, 
subsequent  double-stranded DNA sequencing was performed by the 
dideoxy termination method  (32) to confirm that nucleotide substi- 
tution(s) took place in the expected position(s). The entire 807-bp 
PCR fragment of a  representative  clone(s) of each amino acid muta- 
tion was also sequenced by subcloning the fragment into M13 bacte- 
riophage to determine  whether  random mutation(s) were introduced 
by Taq polymerase. The clones analyzed in this study either were 
free of random mutations or contained  random mutations  that did 
not  alter  the amino  acid sequence. 
Eukaryotic Expression-The wild type and  mutated  ratPDE3 
cDNAs were inserted  into  the EcoRI site of pCMV5, a eukaryotic 
expression vector (33). After transformation of DH5a bacteria, am- 
picillin-resistant cells were examined for the presence and  the orien- 
tation of the  ratPDE3 cDNAs. Plasmids were prepared from 1-liter 
bacterial cultures  as described above. Mouse Leydig tumor cells (MA- 
10) were grown in the medium as described previously (34). When 
MA-10 cells in 10-cm dishes reached a  density of approximately 40% 
of confluency, the cells were transfected with 10 pg  of plasmid DNA 
using a calcium phosphate procedure as described previously (35). 
After an overnight  incubation with the  plasmid/CaP04 mixture, the 
cells were shocked with 10% glycerol in medium for 1.5 min at room 
temperature, washed with PBS, and then incubated in the growth 
medium overnight. To harvest, the cells were washed with PBS, 
scraped with a rubber policeman, and homogenized in an all-glass 
Dounce homogenizer (30 strokes) in a buffer containing 20 mM Tris- 
C1, pH 8.0, 10 mM NaF, 1 mM EDTA, 0.2 mM EGTA, 50 mM 
benzamidine, 0.5 pg/ml leupeptin, 0.7 pg/ml pepstatin, and 2 mM 
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FIG. 3. Schematic representation 
of the strategy used for internal 
deletions within the amino-terminal 
region of ratPDE3. Internal deletions 
of different lengths (291, 393, and 492 
bp) were generated  using PCR  tech- 
nique. Fragments of the  ratPDE3 cDNA 
were amplified using the  ratPDE3 cDNA 
as template  and paired oligonucleotides, 
C and D, E and D, and F and B, as 
primers (also see Fig. 1). To create dele- 
tions starting at the StuI site of the 
cDNA, the primers C, E, and F were 
designed to  contain a StuI sequence a t  
their 5’ ends. The complete sequences 
and base  locations of these  primers  are 
reported under  “Experimental  Proce- 
dures”  and in Fig. 1. PCR products were 
digested with either StuI and XbaI or 
StuI and KpnI restriction enzymes to 
generate  the  StuI-XbaI or StuI-KpnI 
fragment, followed  by ligation to  the 
expression vector to replace the wild- 
type fragment.  Plasmids thus con- 
structed have deletions  within the 5’  re- 
gion of the  ratPDE3 cDNA starting at  
the base position 295 to the positions 
585, 687, and 786, which correspond to 
the locations of primers C, E, and F, 
respectively (see Fig. 1).  The  StuI-KpnI 
fragment was used to create the 295- 
786-bp  deletion  instead of the more ob- 
vious StuI-XbaI fragment,  since the 
small size of the StuI-XbaI fragment  (44 
bp) made it difficult to purify and clone. 
The proteins thus produced have dele- 
tions of 97 amino acids (from T Y ~ ‘ ~  to 
L Y S ’ ~ ~ ) ,  131 amino acids (from Tyr4’ to 
Lys’”), and 164 amino acids (from Tyr” 
to  Thr’12). Since the deletions were pro- 
duced internally, the translation start 
site  (at base 151) of these  mutants was 
unchanged. 






phenylmethylsulfonyl fluoride. The cell homogenates were centri- 
fuged for 15 min at  14,000 X g, and  the soluble fraction was subjected 
t o  PDE assay, immunoprecipitation, or ion-exchange chromatogra- 
phy purification.  “Mock”-transfected cells were treated exactly the 
same way but did not receive plasmid DNA. 
PDE Assay-PDE activity was measured  according to  the method 
of Thompson and Appleman (36) and as detailed previously (37). 
Briefly, bacterial or MA-10 samples were assayed in a total volume 
of 200 pl of reaction  mixture  including 40 mM Tris-C1 (pH 8.0), 10 
mM Mg Cl,, 1.25 mM 2-mercaptoethanol, 1 p M  CAMP, 0.14 mg of 
bovine  serum  albumin, and 1 p~ [3H]cAMP (0.1 pCi). After incuba- 
tion  at 34 “C for 5 min, the reaction was terminated by adding an 
equal volume of 40 mM Tris-C1, pH 7.5, solution containing 10 mM 
EDTA followed by heat denaturation for 1 min. To each reaction 
tube 50 pg of C. atrox snake venum was added, and  the incubation 
was continued at  34 “C for 20 min. The reaction products were 
separated by anion-exchange  chromatography on AG 1-X8 resin, and 
the  amount of radiolabeled adenosine collected was quantitated by 
scintillation counting. Protein concentrations of the samples were 
measured according to Lowry et al. (38). To study the kinetic char- 
acteristics of the recombinant proteins, rates of cAMP hydrolysis 
were determined at  the incubation times of 2, 4, 6, and 8 min with 
increasing concentrations of unlabeled cAMP (0.156-10 p ~ ) .  Data 
were plotted according to Lineweaver and Burk  (39).  For  inhibition 
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rolipram, lo-@ to 3 X M RO 20-1724, or to M milrinone 
which were dissolved in dimethyl sulfoxide. Control tubes contained 
equal amounts of dimethyl sulfoxide. 
Immunoprecipitation-The soluble fraction of MA-10 cells trans- 
fected with plasmid DNAs was immunoprecipitated with the  anti- 
serum K l l l  using fixed Staphylococcus aureus cells (Pansorbin cells) 
by procedures described previously (25). The antigen-antibody com- 
plexes were prepared in a  final  concentration of 1 X sample buffer 
for Western blot analysis. 
Western Blot Analysis-Bacterial lysates and immunoprecipitated 
MA-10 samples were prepared in 1 X sample buffer (62.5 mM Tris- 
C1, pH 6.8, 10% glycerol, 2% (w/v) SDS, 0.7 M 2-mercaptoethanol, 
and 0.0025% (w/v) bromphenol  blue). The samples were boiled for 5 
min and subjected to electrophoresis on a 10% SDS-polyacrylamide 
gel (SDS-PAGE). The proteins were then blotted onto Immobilon 
membrane followed by blocking the membrane in a PBS solution 
containing 5% (w/v) nonfat dry milk and 0.05% (w/v) Tween 20. 
After blocking, the membrane was incubated  with  primary  antiserum, 
KllO or K111, at  a  dilution of 1: lOO in blocking buffer. Antisera KllO 
and K l l l  were raised against  synthetic peptides of ratPDE3 located 
at  the  amino acid positions 416 to 431 and 105 to 126, respectively. 
The  antisera have been characterized previously.’ After KllO  anti- 
’ M. Conti, J. Odeh, J. V. Swinnen,  and M. E. Svoboda, manuscript 
submitted. 
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serum incubation, the membrane was washed in PBS, followed by 
incubation with  peroxidase-conjugated  goat anti-rabbit  antibody a t  a 
1: lOOO dilution in blocking  buffer.  After washing  with  PBS, peroxi- 
dase was visualized with the  HRP color development  reagent  (Bio- 
Rad) in the presence of hydrogen peroxide. For K l l l  antiserum 
staining,  the  membrane was washed  with PBS  containing 1% (w/v) 
Nonidet  P-40  and 0.2% (w/v)  Tween 20, followed by incubation with 
"..'I-protein A (0.5 pCi/ml) in blocking buffer. After washing with 
PBS  the  membrane was exposed to XAR-5  x-ray film. 
Ion-exchange Chromatography-The  soluble fraction of transfected 
MA-10  cells  was prepared  as described  above and  then were applied 
to a  high-performance liquid chromatography  DEAE  column for the 
partial purification of recombinant  PDEs.  The  conditions  and  pro- 
cedures used for the column is  detailed in Ref. 34. The  PDE  activity 
of each fraction was measured  and  the  activity recovered from the 
columns was corrected for the  amount of protein loaded. The  fractions 
containing the recombinant PDEs were subjected to kinetic and 
inhibition  studies. 
RESULTS 
Expression of Wild Type ratPDE3  in  Prokaryotic  and  Eu- 
karyotic Cells-The complete  nucleotide and deduced amino 
acid sequences of ratPDE3  are  reported in Fig. 1. As previ- 
ously reported, expression of this cDNA  in E. coli leads  to  the 
appearance of cAMP hydrolytic activity  with  properties  iden- 
tical  to  those of a CAMP-PDE purified from  rat  Sertoli cell 
(24, 25). SDS-PAGE  and  Western  analysis  using  KllO  anti- 
body of bacterial extract expressing recombinant ratPDE3 
demonstrated  the presence of a 70-71-kDa immunoreactive 
band  (see Figs. 4 and 8). An additional  doublet of 47-50 kDa 
was also present in  all experiments  performed (Figs.  4 and 8). 
This  is probably  derived  from  endogenous  proteolysis of the 
amino  terminus of the  PDE  protein,  since  this  doublet could 
not be detected  with  the K l l l  antibody which  recognizes an 
epitope located at  amino acid position 105-126 of the  protein 
(data  not  shown).  This molecular  weight  species is most likely 
catalytically inactive (see below). Identical results were ob- 
tained with a modified cDNA lacking 147 bases of the 5'- 
untranslated region (see Fig. 1 for the location of the  EcoRI 
site).  This modified cDNA  was  used for all experiments re- 
ported below. 
Mapping of the Catalytic Center of ratPDE3 Enzyme by 
Deletion Mutation-To determine if the conserved region 
corresponds  to  the  catalytic  domain of ratPDE3,  constructs 
bearing deletions of 5' and/or 3' domain  flanking  the  con- 
served region were generated  based  on  the  strategy  outlined 
in Fig. 2B. Since  the  initiation codon of the wild type cDNA 
(at  the base  position 151) was removed from  deletion of the 
5' domain (constructs B and C), an  AUG codon present 
immediately  5' to  the XbaI site  in  the oligomer A was designed 
to  initiate  the  translation of these  amino-terminal  truncated 
proteins. Similarly, the  stop codon added immediately 3' to 
the  KpnI  site in the oligomer B was used to  terminate  the 
translation of those  proteins  truncated at   the carboxyl ter- 
minus (constructs A and C). The  three  truncated  ratPDE3 
proteins  thus  generated are: one  with a deletion of 99 amino 
acids at   the carboxyl terminus  (construct  A),  one  with deletion 
of the  entire 224 amino acids at  the  amino  terminus  (construct 
B), and one containing only the 261 amino acids of the 
conserved region of ratPDE3  (construct C). The  three  con- 
structs were expressed  in E. coli, and  PDE  activity was  meas- 
ured in bacterial lysates. Only expression of the construct 
bearing a 99-amino acid  deletion at   the carboxyl terminus led 
to   the appearance of a  major immunoreactive  PDE  protein of 
53-55 kDa (Fig 44). This truncated protein retained the 
ability  to catalyze cAMP hydrolysis (PDE  activity of bacterial 
lysate,  pmoles/min/mg  protein:  antisense  construct, 9.8 f 2.1; 
wild type construct, 176.8 & 4.9; carboxyl-deletion construct, 
67.0 f 15.0; also see  Fig 5 ) .  This  indicated  that  the carboxyl- 
kD; kC 
runcated ratPDE3 in 
I in samde buffer. frac- 
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FIG. 4. Expression of wild-type and t 
E. coli. Bacteria were grown,  pelleted, lysed 
tionated by SDS-PAGE,  and  immunostained with K i l o  antibody  as 
described under  "Experimental Procedures." Lysates were prepared 
from bacteria  transformed with plasmids  containing  one of the fol- 
lowing inserts:  the full length ratPDE3 cDNA inserted in antisense 
orientation or in sense orientation (wild-type), the ratPDE3 cDNA 
deleted at   the 3' end (COOH deletion; A ) ,  or deleted by an  internal 
fragment  in  the  5' region ( E ) .  The sizes of internal deletions are  as 
indicated.  Eighty pg (in A )  or 40 pg (in B )  each of lysate protein was 
applied to  the gel. 
terminal  fragment of ratPDE3  is  not necessary for catalysis. 
In  contrast,  the expression of the  other two constructs did 
not result in any detectable PDE activity. These truncated 
proteins, however, were expressed at  a low level in bacteria 
(data not shown), rendering the interpretation of the data 
difficult. 
To  overcome the  potential  disparity in the level of expres- 
sion of the deleted proteins with different  translation  initia- 
tion  sites,  an  alternative  strategy of nested  deletions was used 
to  obtain  deletions  in  the  amino-terminal region. In addition 
to the ratPDE3 cDNA used in the present study, another 
clone, designated ratPDE3.2 (24), has previously been re- 
trieved from a Sertoli cell library. The ratPDE3.2 cDNA 
contains an open reading frame coding for the ratPDE3 
protein  that  lacks  78  amino acids at  the  amino  terminus (Fig. 
1). This  truncated  protein gave rise to  an active  enzyme when 
expressed in  bacteria  (24),  indicating  that  this region is not 
necessary for catalysis. On the basis of this observation, a 
series of internal deletions starting at  the  StuI  site (corre- 
sponding  to  the  amino acid  position 49) within the 5' region 
of the  ratPDE3 cDNA were constructed using PCR technique. 
The  method for generating  different  length  deletions between 
StuI  and  XbaI  sites  is  detailed  in Fig.  3. The  three  constructs 
with  deletions from base 295 to 585, to 687 and  to 786 were 
predicted to direct  the  translation of truncated  proteins lack- 
ing  amino acids 49 through 145 (97-aa  deletion),  amino acids 
49 through 179  (131-aa deletion),  and  amino acids 49 through 
212 (164-aa deletion), respectively. Western blot  analyses of 
bacterial  lysates  expressing  these  truncated  proteins showed 
immunoreactive  bands of 60-61, 57-58, and 54-55 kDa, re- 
spectively (Fig. 4B).  These molecular  masses were comparable 
to  those  predicted by the size of the deletions. In addition, 
the efficiency of expression of these  truncated  proteins was 
similar  to  that of the wild type enzyme  (Fig. 4B).  When  the 
internal  97-amino acid fragment was removed from the  PDE, 
cyclic AMP-hydrolyzing activity observed was consistently 2- 
%fold greater than the wild type enzyme (Fig. 5). Further 
deletions produced completely inactive proteins when ex- 
pressed  in bacteria (Fig. 5). A similar conclusion was reached 
when these  truncated  proteins were expressed  in  eukaryotic 
cells. Expression of the  PDE  with  the  97-amino acid deletion 
in MA-10 cells  produced  a protein with  approximately twice 
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FIG. 5. Comparison of the PDE activity of wild-type and truncated ratPDE3. Bacteria were grown, pelleted, lysed in homogeni- 
zation buffer, and assayed for PDE activity as described under  "Experimental Procedures." Lysates were prepared from bacteria  transformed 
with plasmids containing different DNA inserts. Antisense, the full length ratPDE3 cDNA inserted in antisense  orientation, representing the 
basal level of PDE activity. Wild  type, the  ratPDE3 cDNA inserted in sense orientation, serving as a positive control. Deletions, DNA inserts 
encoding truncated ratPDE3 proteins including 97-, 131-, and 164-amino  acid  deletion (Tyr4'-Lys14', T ~ r ~ ' j - L y s ' ~ ~ ,  and Tyr49-Thr212, 
respectively)  within the  amino-terminal region and 99-amino  acid  deletion  (Ser486-Thr584) at  the carboxyl terminus. PDE activity  represents 
the mean f S.E. of at  least three independent experiments  (triplicate  determinations of each experiment). Bacterial lysate was prepared 
independently in each  experiment. The left  hatched bur indicates the  amino-terminal region of 48 amino acids  unchanged in the deletion 
mutations. 
TABLE I 
Comparison of the  properties of wild type  and  truncated  ratPDE3  expressed in E. coli and MA-10 cells 
Values of the  apparent K, (pM) and VmaX (nmoles/min/mg protein) were determined for the wild type and  truncated  ratPDE3. Deletions 
introduced were the 97-amino acid internal deletion at  the  amino  terminus  (NH, 97-aa deletion) and  the 99-amino acid deletion at  the 
carboxyl terminus (carboxyl-terminal  deletion).  Bacteria were lysed in homogenization buffer, and  the lysate was directly used in the assay. 
MA-10 cells were harvested, and  extracts were prepared as described under "Experimental  Procedures." The recombinant PDE was partially 
purified by DEAE ion exchange  chromatography, and  the fractions containing  the recombinant  activity were used for the kinetic determi- 
nations. Each value is the mean k S.E. of more than  three independent  experiments. The number of experiments  is  reported in parenthesis. 
The Vmn* values for the eukarvotic exoression are  the  means of two  indeoendent  exoeriments. 
Bacterial expression Eukaryotic cell expression 
K, VU,*x K"? Vmax 
Wild type 2.84 f 0.62 (5) 0.36 f 0.09 (5) 2.02 k 0.30 (4) 9.90 
Carboxyl-terminal  deletion 3.73 f 1.96 (5) 0.24 k 0.10 (5) 
NH, 97-aa  deletion 2.36 f 0.25 (4) 1.04 f 0.04 (4) 1.81 k 0.25 (3) 20.26 
Expression in eukaryotic cells of ratPDE3 bearing  a  deletion at  the carboxyl terminus did not produce a  significant  accumulation of the 
deleted  protein. 
the activity of the wild type  (Table I). Conversely, in agree- 
ment with what has been shown in  bacteria, the 131-amino 
acid truncated protein expressed in MA-10 cells was inactive 
(data not  shown). The lack of PDE activity of the  internal 
131- and 164-amino acid deletions further indicated that  the 
observed doublet of  47-50 kDa in the Western  blots (Figs. 4 
and 8) has no enzyme activity. 
Catalytic Properties of the Truncated ratPDE3 Enzyme- 
Measurement of the  apparent K,,, of the crude or partially 
purified enzyme with 97 amino acids deleted within the amino 
terminus expressed in  bacteria or eukaryotic cells showed no 
significant difference from that of the wild type (Table I). 
The deletion at  the carboxyl terminus .produced an enzyme 
with similar or slightly decreased affinity for the cAMP  sub- 
strate. Maximal velocities of the enzymes, however, were 
affected (Table I). The kinetics of cAMP hydrolysis were 
linear in all cases indicating a homogeneous catalytic site 
(data not shown). In addition,  deletions at  the amino and  the 
carboxyl termini did not abolish the  PDE inhibition by roli- 
pram, RO 20-1724, or milrinone (Fig 6).  This indicated that 
the deleted regions are not involved in the interaction with 
these inhibitors. In  the  three experiments performed it was 
noticed that  the  PDE bearing the 99-amino acid deletion at  
the carboxyl terminus was more sensitive to milrinone than 
the wild type (ED50: wild type, 7.73 f 1.10 p ~ ;  carboxyl- 
terminal deletion, 3.10 f 0.48 pM). 
Site-directed Mutagenesis of ratPDE3 Enzyme-Several 
lines of evidence indicate that a  Ser, Thr,  or His residue plays 
an important role in PDE catalysis (20-23). To assess the 
role of these residues in  the  structure of ratPDE3 catalytic 
site, all the Ser and  Thr residues present in the conserved 
domain and identical  in all PDEs,  and two of the conserved 
histidine residues were systematically mutated to Ala or other 
residues (Fig  7). None of the mutations  obtained  altered the 
level of the  PDE protein expressed in  bacteria (Fig 8). On the 
other hand, changes were observed in the activity of the 
mutated  proteins (Table 11). Substitution of the  Thr present 
at  the position 349 to Ala or  Pro (Thr349/Ala or Thr349/Pro) 
produced a completely inactive PDE protein.  Substitution of 
the same Thr residue with Ser (Thr349/Ser mutation) pro- 
duced a  protein  still displaying catalytic activity, even though 
the velocity of the reaction was markedly reduced. The mu- 
tations of 2 Ser residues present at  the positions 305 and 398 
either did not affect catalysis or produced a decrease in the 
catalytic activity. Substitutions of Hisz7' and His311 resulted 
in  a complete inactivation of the enzyme. 
Several lines of evidence indicate that  the Glu residue at 
position 204  of the RII, regulatory subunit of CAMP-depend- 
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en t  protein  kinase  participates  in  the  cAMP binding,  probably 
forming an  hydrogen bond  with  the 2'-hydroxyl  group of the 
ribose of cAMP (16). Naturally occurring mutation of the 
conserved Gly residue adjacent  to  this Glu disrupts  the  cAMP 
binding (17-19). An identical  stretch of 7 amino acids, ELAL- 
MYN,  surrounding  this  Glu  in RII. is  present  in all CAMP- 
PDEs  thus  far sequenced. To  test  whether  this region has a 
similar  function  in  the  CAMP-PDE,  the residue (SerZg5)  ad- 
jacent  to  the  ELALMYN was mutated  to Gly or Glu (Fig. 7), 
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FIG. 6. Effects of PDE inhibitors on the activity of wild- 
type and truncated ratPDE3. Bacteria were lysed in homogeni- 
zation buffer and assayed for PDE  activity  as described under  "Ex- 
perimental Procedures." Lysates were prepared from bacteria that  
expressed  the wild-type ratPDE3 (A)  or truncated  proteins:  97-amino 
acid deletion within the amino-terminal region ( B )  and 99-amino 
acid deletion at the carboxyl terminus (C). PDE activity  was  assayed 
in the  absence of the PDE inhibitors which represents  the  maximum 
activity (pmol/min/pl lysate: wild type, 0.94; NH, deletion, 2.37; 
carboxyl deletion, 0.32) and  in  the presence of lo-@ to M rolipram, 
lo-' to 3 x M RO 20-1724, or to M milrinone.  Each 
point represents the mean of triplicate determinations of a repre- 
sentative  experiment of three performed.  EDSO  values in pM for the 
three  inhibitors are:  rolipram: wild type, 0.36 t 0.08; NH, deletion, 
0.94 & 0.16; carboxyl-terminal  deletion, 0.50 k 0.10; RO 20-1724: wild 
type, 1.89 t 0.37; NH, deletion, 3.13 t 0.52; carboxyl-terminal dele- 
tion, 2.34 & 0.53; milrinone: wild type, 7.73 & 1.10; NHz deletion, 10.9 
& 1.51; carboxyl-terminal  deletion, 3.10 & 0.48 (mean & S.E. of three 
independent  experiments). 
tion of the SerZg5 with Gly led to some  reduction in  catalytic 
activity of the PDE. Unlike what was observed for RII., 
mutation  to Glu in  ratPDE3  did  not  abolish enzyme  activity 
(Table 11). It indicates that this region of the protein can 
accept modifications  which in RII, disrupts  the  structure of 
the  binding  site. 
Characterization of the  Thr349/Ser Mutation-To further 
analyze  the effect of Thr349/Ser  mutation,  the  CAMP-PDE 
carrying this substitution was inserted into a mammalian 
expression vector and expressed in COS and MA-10 cells. 
Data  obtained  in MA-10 cells will be reported here, although 
COS cell expression  produced similar results. Immunoprecip- 
itation of the soluble fraction of mock-transfected cells and 
cells transiently  transfected  with  the wild type or Thr349/Ser 
mutant  construct was followed by SDS-PAGE  and  immuno- 
blot analysis. The expression of the  Thr349/Ser  mutation was 
comparable  to  that of the wild type  (Fig  9).  On  the  contrary, 
the  amount of PDE  activity recovered after  transfection of 
the Thr349/Ser mutation was only a small fraction of the 
activity recovered with wild type  PDE  (PDE activity,  pmol/ 
min/mg protein: mock, 21.1; wild type, 646.8 Thr349/Ser, 
58.5). To further characterize the kinetic properties of the 
Thr349/Ser  PDE,  the wild type,  and  the  Thr349/Ser-mutated 
PDEs were partially purified on  HPLC ion-exchange column, 
a method that allows separation of the recombinant PDE 
activity  from  the endogenous PDE  (Fig 10). A  major  differ- 
ence  in  the  activity was retained  after  this  chromatography. 
Comparison of the  kinetics of these  partially purified PDEs 
showed  a significant difference in  the  apparent K,,, (wild type, 
2.06 p ~ ;  Thr349/Ser  mutant, 3.55 p ~ )  of the enzyme. Fur- 
thermore,  the  apparent V,,, of the  Thr349/Ser  protein was 
approximately 10% of that of the wild type protein. The 
inhibition of the  catalytic  activity of the  Thr349/Ser  mutant 
by different  PDE  inhibitors was comparable  to  that of the 
wild type  protein  (data  not  shown). 
DISCUSSION 
Although information is available about the presence of 
different  domains of the  CaM-PDE  (8,9),  cGS-PDE (10-12), 
and  photoreceptor  PDE (12), little  is  known  about  the  struc- 
ture of the  CAMP-PDE  family of enzymes. This  is a group of 
PDEs which  catalyzes cAMP  degradation  with a low K,,, and 
whose activity  is  under  hormonal  control (8). Data  reported 
show that these PDEs may play an important role in the 
mechanism of regulation of cell responses to  hormones (25, 
34, 42, 43). In the present study we have provided direct 
evidence that the catalytic domain of the CAMP-PDE is 
located  in a central region of the  protein which contains  the 
domain conserved in  most  PDEs. We  have  also  identified  a 
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FIG. 8. Expression of wild type and mutated  ratPDE3  in E. 
coli. Bacteria were transformed with plasmids  containing  either  the 
full length ratPDE3 cDNA inserted in antisense orientation or in 
sense orientation (wild-type) or mutated ratPDE3 cDNA encoding 
proteins with a single amino acid substitution. The blot was immu- 
nostained with KllO  antiserum.  Forty-five pg each of lysate  protein 
was applied to  the gel. 
TABLE I1
Phosphodiesterase  activities of wild type  and  mutated ratPDE3 
expressed in  E. coli 
Bacteria were transformed with plasmids containing either the 
wild type  ratPDE3 cDNA inserted  in  antisense  or  sense  orientation 
or  mutated  ratPDE3 cDNA encoding proteins with a single amino 
acid substitution. Cells were lysed and assayed for activity as de- 
scribed under  “Experimental Procedures.” Results  are  the  means f 
S.E.M. of a t  least  three  independent  experiments  assayed  in  triplicate. 
ratPDE3 construct PDE activity 
pmollminlmg protein 
9.8 f 2.0” 
76.8 f 4.9 
47.8 f 4.2 
74.7 f 6.1 
74.5 f 1.5 
80.8 f 0.3 
52.3 f 9.5 
20.8 f 2.0 
2.5 f 0.5 
1.8 f 0.3 
1.4 f 0.3 
6.7 f 0.6 
2.1 f 0.3 
3.1 f 1.0 
“ Mean f S.E.M. 
that  play an  important role in the  structure  and  function of 
the catalytic  site. 
The following lines of evidence identify  the  catalytic do- 
main of this  CAMP-PDE  (ratPDE3). An initial  observation 
made in our laboratory has shown that a complementary 
DNA encoding a CAMP-PDE missing the  first 78 amino acids 
of ratPDE3 enzyme  when  expressed in  bacteria leads to  the 
appearance of an active  enzyme,  suggesting that  the  amino- 
terminal region is not  part of the  catalytic  domain (24). The 
deletion mutations described herein have allowed the  identi- 
fication of a region that  contains  all  the  information necessary 
for catalysis. Since  the enzyme with  the  97-amino acid  dele- 
tion (Tyr4’-Lyd4’) is active and  that  with  the  131-amino acid 
deletion (Tyr49-Lys’79) is inactive, the  beginning of the  cata- 
lytic domain should be  located  between Leu’4fi and Lys”’. At 
the carboxyl terminus, Gln4” is the tentative end of the 
catalytic  domain, because further  deletions  from Gln48s toward 
the  amino  terminus were not performed. This roughly coin- 
cides  with the conserved domain of approximately 35-37 kDa. 
18.4 
FIG. 9. Immunoblot of wild type and  Thr349/Ser  ratPDE3 
expressed in MA- 10 cells. Cells were either  mock-transfected (lane 
1 )  or  transiently  transfected with the wild type  construct (lane 2 )  or 
the  Thr349/Ser  mutant  construct (lane 3). Cells were harvested, and 
the supernatants were prepared and immunoprecipitated with the 
antiserum K l l l  as described under  “Experimental Procedures.” The 
resulting  antigen-antibody complexes were solubilized and  fraction- 
ated by SDS-PAGE followed by immunostaining with the same 
antiserum. The 53-kDa band corresponds to the immunoglobulin 
used for the immunoprecipitation, since it was also present in the 
immunoprecipitated  sample  without cell extracts.  The  97-kDa band 
probably  corresponds  to  the ndogenous CAMP-PDE, since this band 
could not be detected in the recombinant PDE samples that have 
been partially purified through a DEAE column (data not shown). 
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FIG. 10. Ion-exchange chromatography of wild type and 
Thr349/Ser  ratPDE3 in MA-10 cells. Mock- or  ratPDE3-trans- 
fected  cells were harvested,  and  extracts were prepared and  fraction- 
ated on a  DEAE column, as described under  “Experimental Proce- 
dures.’’ The  PDE  activity  present  in each  fraction was measured and 
was corrected for the  amount of protein loaded on the column. The 
column profiles of wild type  and  Thr349/Ser  ratPDE3 ( A )  and mock 
transfection  and  Thr349/Ser  ratPDE3 ( R )  are reported. The broken 
line shows  the sodium acetate  gradient applied to  the column. The 
results of a representative experiment of the two performed are 
shown. 
Interestingly,  this  is  similar  to  the size of the active  fragment 
obtained by controlled proteolysis of a CaM-PDE  (9), a  cGS- 
PDE (lo),  and a photoreceptor PDE (12). The 35-37-kDa 
fragment includes the region (LyS”4-A~n4R”) conserved in 
most  PDEs,  but  it is not limited to  this domain. In fact, an 
additional region of 68 amino acids flanking the conserved 
domain  toward  the  amino  terminus  appears  to be necessary 
for  catalysis. DNA  sequence analysis  indicates  that  this frag- 
ment is conserved among the different CAMP-PDE forms, 
suggesting again  an  important  function for this region. How- 
ever, no homology was found  with the  PDEs of other families. 
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The  data showed that  the  ratPDE3 protein  bearing  a dele- 
tion of amino acids 49-145 (NH2 97-aa deletion) not only 
retains catalytic activity but also that the velocity of the 
reaction catalyzed by this  truncated protein is approximately 
2-3-fold higher than  that of the wild type protein. Since the 
activities have been measured in crude or partially purified 
PDE preparations, it  cannot be excluded that differences in 
activity are due to differences in the level of expression or in 
protein stability. If our preliminary data are confirmed with 
a purified enzyme it would  be an indication that within this 
97-amino acid region there is a domain that inhibits the 
catalytic activity. This would be reminiscent of what is ob- 
served for other PDEs (8). It is accepted that regulatory 
domains  present  in  a  CaM-PDE  exert an inhibitory constraint 
on  the catalytic domain. Proteolytic removal of these  domains 
causes an irreversible activation of the  CaM-PDE together 
with loss of calmodulin regulation (8, 9). Thus, it can be 
speculated that  CAMP-PDEs also have regulatory domain(s) 
similar to  the CaM-PDE. The identity of the regulatory signal 
that modulates the function of this domain in the CAMP- 
PDE is not known. 
The location of the catalytic domain within the fragment 
included between and Ser486 is also supported by site- 
directed mutagenesis of residues within this region. Of the 6 
residue substitutions performed, only one (Ser398) had no 
effect on catalysis. All the other mutations decreased or 
abolished catalytic activity of the PDE. This is a further 
indication that these residues are located in the catalytic 
center of the enzyme. 
Substitution of His278, His3I1, and Thr349 abolished the 
catalytic activity of the enzyme. At present we cannot  distin- 
guish whether these residues participate in catalysis or are 
necessary for the conformation of the catalytic  center. The 
finding that Thr349 could be substituted by a  Ser with reten- 
tion of some catalytic activity, while substitution with an 
alanine gave rise to  an inactive enzyme is an indication that 
the hydroxyl group present in  Thr349  and Ser349 may play an 
important role in enzyme function. It is to be emphasized that 
Thr349 is present in the most conserved region of all PDE 
sequences available (6). In  this region 7 residues are  identical 
or conserved. Interestingly, it has been found that in 5‘- 
nucleotide phosphodiesterase a Thr residue plays an impor- 
tant role in catalysis, because it forms an intermediate bond 
with phosphate (23). Similarly, data thus far accumulated 
using cAMP analogs with different group substitutions have 
suggested that an electron donor residue such as Thr is 
required in the  PDE for the nucleophilic attack of the phos- 
phodiester bond (21,22). It is, therefore,  tempting to speculate 
that  this  Thr  has a crucial function  in PDE catalysis. 
Chen et al. (14) first observed that in Drosophila dunce 
PDE there is a short segment (ELALMYN) of identity  with 
the RII, subunit of CAMP-dependent protein kinase. In  the 
regulatory subunit of the kinase the Glu residue present  in 
this region  is thought  to play a crucial role in stabilizing the 
binding of cAMP to  the protein by forming a hydrogen bond 
with the 2”hydroxyl group of the ribose moiety of cAMP 
(16). However, our mutation data provide evidence that  the 
ELALMYN region behaves differently in  the  CAMP-PDE.  In 
RII., substitution of the Gly residue adjacent to  this region 
with Glu disrupts cAMP binding. Conversely, an identical 
substitution in the  CAMP-PDE  has only marginal effects on 
catalysis. This is in line with the observation that 2“deoxy 
cAMP lacking the hydroxyl group at  the position 2’ competes 
efficiently for the catalytic domain of several PDEs (21, 22, 
and our laboratory). This suggests that, unlike RIIa, there is 
probably no hydrogen bond formed between 2’-OH of cAMP 
and  the Glu residue of ELALMYN in the  CAMP-PDE.  There- 
fore, even though this sequence is present in the catalytic 
center of the  CAMP-PDE,  it probably has a  different function. 
In summary,  these data demonstrate that a 37-kDa frag- 
ment of a CAMP-PDE  contains  the catalytic domain of the 
protein. It also contains the site of interaction with the 
selective inhibitors RO 20-1724 and rolipram. Within this 
region the  Thr349 residue conserved in the  CAMP-PDEs  and 
in  other  PDEs plays an  important role in the catalytic  center. 
Conversely, the role of the amino and carboxyl terminus 
domains remains largely unknown. Preliminary evidence re- 
ported suggests the presence of a regulatory domain located 
at  the amino terminus of the protein. 
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